Retracted Chapter: EuroFlow-Based Next-Generation Flow Cytometry for Detection of Circulating Tumor Cells and Minimal Residual Disease in Multiple Myeloma

2018 ◽  
pp. 15-34 ◽  
Author(s):  
Leire Burgos ◽  
Bruno Paiva
Keyword(s):  
Multiple Myeloma ◽  
Flow Cytometry ◽  
Tumor Cells ◽  
Minimal Residual Disease ◽  
Circulating Tumor Cells ◽  
Residual Disease ◽  
Next Generation ◽  
Minimal Residual

Minimal residual disease and quality sample evaluation by Next Generation Flow cytometry in multiple myeloma patients: a Brazilian experience

2019 ◽  
Vol 19 (10) ◽  
pp. e179
Author(s):  
Anna Beatriz Salgado ◽  
Roberia Mendonça de Pontes ◽  
Roberto Jose Pessoa de Magalhaes Filho ◽  
Eduarda Barbosa ◽  
Hélio Dutra ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Flow Cytometry ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Next Generation ◽  
Minimal Residual

Minimal residual disease in multiple myeloma: an important tool in clinical trials

2021 ◽  
Vol 16 ◽  
Author(s):  
Alessandro Gozzetti ◽  
Monica Bocchia
Keyword(s):  
Multiple Myeloma ◽  
Clinical Trials ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
New Drugs ◽  
Next Generation ◽  
Depth Of Response ◽  
Next Generation Sequencing Ngs ◽  
Future Therapy ◽  
Minimal Residual

: Minimal residual disease (MRD) detection represents a great advancement in multiple myeloma. New drugs are now available that increase depth of response. The International Myeloma Working Group recommends the use of next-generation flow cytometry (NGF) or next-generation sequencing (NGS) to search for MRD in clinical trials. Best sensitivity thresholds have to be confirmed, as well as timing to detect it. MRD has proven as the best prognosticator in many trials and promises to enter also in clinical practice to guide future therapy.

Sign in / Sign up

Export Citation Format

Share Document